Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1.

Qu W, Li Y, Hovgaard L, Li S, Dai W, Wang J, Zhang X, Zhang Q.

Int J Nanomedicine. 2012;7:4983-94. doi: 10.2147/IJN.S30013. Epub 2012 Sep 14.

2.

Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system.

Shrestha N, Shahbazi MA, Araújo F, Mäkilä E, Raula J, Kauppinen EI, Salonen J, Sarmento B, Hirvonen J, Santos HA.

Biomaterials. 2015 Nov;68:9-20. doi: 10.1016/j.biomaterials.2015.07.045. Epub 2015 Jul 26.

PMID:
26253804
3.

Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.

Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC.

Bioconjug Chem. 2008 Jan;19(1):334-41. Epub 2007 Dec 14.

PMID:
18078308
4.

A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.

Jia Z, Lin P, Xiang Y, Wang X, Wang J, Zhang X, Zhang Q.

Eur J Pharm Biopharm. 2011 Sep;79(1):126-34. doi: 10.1016/j.ejpb.2011.05.009. Epub 2011 May 30.

PMID:
21658449
5.

Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.

Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, Beglinger C.

Clin Pharmacol Ther. 2009 Dec;86(6):644-50. doi: 10.1038/clpt.2009.159. Epub 2009 Sep 2.

PMID:
19727071
6.

Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.

Youn YS, Chae SY, Lee S, Kwon MJ, Shin HJ, Lee KC.

Eur J Pharm Biopharm. 2008 Mar;68(3):667-75. Epub 2007 Aug 2.

PMID:
17904340
7.

Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A.

Dai W, Guo Y, Zhang H, Wang X, Zhang Q.

Int J Pharm. 2015 Jan 30;478(2):718-25. doi: 10.1016/j.ijpharm.2014.11.030. Epub 2014 Nov 15.

PMID:
25448562
8.

The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium.

Araújo F, Shrestha N, Shahbazi MA, Fonte P, Mäkilä EM, Salonen JJ, Hirvonen JT, Granja PL, Santos HA, Sarmento B.

Biomaterials. 2014 Nov;35(33):9199-207. doi: 10.1016/j.biomaterials.2014.07.026. Epub 2014 Aug 7.

PMID:
25109441
9.

Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.

Hanato J, Kuriyama K, Mizumoto T, Debari K, Hatanaka J, Onoue S, Yamada S.

Int J Pharm. 2009 Dec 1;382(1-2):111-6. doi: 10.1016/j.ijpharm.2009.08.013. Epub 2009 Aug 19.

PMID:
19698772
10.

Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.

Wang XQ, Fan JM, Liu YO, Zhao B, Jia ZR, Zhang Q.

Int J Pharm. 2011 Oct 31;419(1-2):339-46. doi: 10.1016/j.ijpharm.2011.08.003. Epub 2011 Aug 9.

PMID:
21843612
11.

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.

Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J.

Endocrinology. 2008 May;149(5):2038-47. doi: 10.1210/en.2007-0966. Epub 2008 Jan 17.

PMID:
18202141
12.

Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system.

D'Alessio D, Lu W, Sun W, Zheng S, Yang Q, Seeley R, Woods SC, Tso P.

Am J Physiol Regul Integr Comp Physiol. 2007 Dec;293(6):R2163-9. Epub 2007 Sep 26.

13.

Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin.

Li C, Zhang Y, Su T, Feng L, Long Y, Chen Z.

Int J Nanomedicine. 2012;7:5995-6002. doi: 10.2147/IJN.S38043. Epub 2012 Dec 5.

14.

The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.

Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM, Arnold M, Langhans W, Grill HJ.

Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1479-85. doi: 10.1152/ajpregu.00356.2011. Epub 2011 Aug 17.

16.

Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.

Han J, Sun L, Huang X, Li Z, Zhang C, Qian H, Huang W.

Br J Pharmacol. 2014 Dec;171(23):5252-64. doi: 10.1111/bph.12843. Epub 2014 Sep 5.

17.

Development of novel mesoporous nanomatrix-supported lipid bilayers for oral sustained delivery of the water-insoluble drug, lovastatin.

Zhang Y, Zhang H, Che E, Zhang L, Han J, Yang Y, Wang S, Zhang M, Gao C.

Colloids Surf B Biointerfaces. 2015 Apr 1;128:77-85. doi: 10.1016/j.colsurfb.2015.02.021. Epub 2015 Feb 19.

PMID:
25731096
18.

PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.

Youn YS, Jeon JE, Chae SY, Lee S, Lee KC.

Diabetes Obes Metab. 2008 Apr;10(4):343-6. Epub 2007 Nov 22.

PMID:
18034839
19.

Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.

Eldor R, Kidron M, Greenberg-Shushlav Y, Arbit E.

J Diabetes Sci Technol. 2010 Nov 1;4(6):1516-23.

20.

Preparation of a nanoscale baohuoside I-phospholipid complex and determination of its absorption: in vivo and in vitro evaluations.

Jin X, Zhang ZH, Sun E, Qian Q, Tan XB, Jia XB.

Int J Nanomedicine. 2012;7:4907-16. doi: 10.2147/IJN.S35965. Epub 2012 Sep 13.

Supplemental Content

Support Center